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Unfortunately, the original version of this article [1] con-
tained an error. After publication it came to the authors’ 
attention that the figure legends were displayed incor-
rectly. The correct figure legends can be found below in 
this erratum.
Fig. 1 MK-2206 suppressed the cell growth of NB cells. 
a MK-2206 suppressed the cell growth of NB cell lines. 
LAN-1, KP-N-SIFA, NB-19, and SK-N-DZ cells were 
cultured in RPMI1640  +  10  % FBS with MK-2206 at 
indicated concentrations. Cell growth was evaluated as 
cell numbers at 72  h, and it was repeated three times. 
Data are expressed as the mean (±SD). b Photomicro-
graphs of MK-2206 non-resistant and resistant cells. 
Cells were cultured in glass bottom slide chambers with 
RPMI1640  +  10  % FBS, with MK-2206 (resistant sub-
lines)/without MK-2206 (non-resistant cells) overnight. 
A 50  µm scale is indicated (Olympus Fluoview fv1000, 
DIC acquisition, ×40). c MK-2206 showed less inhibition 
in the proliferation of MK-2206-resistant sublines than in 
the non-resistant cells. Indicated cells were cultured in 
RPMI1640 + 10 % FBS with MK-2206 at indicated con-
centrations. Cell growth was evaluated as cell numbers at 
indicated hours, and it was repeated three times. Data are 
expressed as the mean (±SD). *P < 0.01
Fig. 2 MK-2206 showed less inhibition in cell growth of 
MK-2206-resistant sublines. a MK2206 suppressed cell 
growth in a dose dependent method, and MK-2206-re-
sistant sublines maintained resistance after 2-week 
withdrawal of MK-2206. Indicated cells were cultured in 
RPMI1640  +  10  % FBS with MK-2206 at the indicated 
concentrations. Cell growth was evaluated as cell num-
bers at 72  h, and it was repeated three times. Data are 
expressed as the mean (±SD). b IC50 of MK-2206 in indi-
cated cells. c The effect of MK-2206 on cell cycle phase 
distribution. LAN-1 and LAN-1-MK were treated with/
without MK-2206 (5 µM) in RPMI1640 with 10 % FBS for 
12 h followed by analysis of cell cycle phase distribution, 
as introduced in “Methods”. Cells were stained with pro-
pidium iodide (PI) for 30 min followed by FACScan flow 
cytometer. d Column chart of cell cycle distribution in c
Fig. 3 Effect of GSK2334470 (GSK), PDK1 inhibitor, in 
MK-2206-resistant sublines compared with non-resistant 
cells. a Indicated cells were treated with GSK at indi-
cated concentrations, with/without MK-2206 (5  µM) in 
RPMI1640 + 10 % FBS. Cell growth was evaluated as cell 
numbers at 72  h, and it was repeated three times. Data 
are expressed as the mean (±SD). b IC50 of GSK in indi-
cated cells. c The effect of GSK on cell cycle phase distri-
bution in LAN-1 and LAN-MK. LAN-1 and LAN-1-MK 
were treated with GSK (5  µM) with/without MK-2206 
(5 µM) in RPMI1640 with 10 % FBS for 12 h followed by 
analysis of cell cycle phase distribution, as introduced 
in “Methods”. Indicated cells were stained with PI for 
30 min followed by FACScan flow cytometer
Fig.  4 Effect of AZD8055 (AZD), mTOR inhibitor, in 
MK2206 resistant sublines compared with non-resistant 
cells. a Indicated cells were treated with AZD at indi-
cated concentrations, with/without MK-2206 (5  µM) in 
RPMI1640 + 10 % FBS. Cell growth was evaluated as cell 
numbers at 72  h, and it was repeated three times. Data 
are expressed as the mean (±SD). b IC50 of AZD in indi-
cated cells. c The effect of AZD on cell cycle phase distri-
bution in LAN-1 and LAN-MK. LAN-1 and LAN-1-MK 
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were treated with AZD (50 nM) with/without MK-2206 
(5 µM) in RPMI1640 with 10 % FBS for 12 h followed by 
analysis of cell cycle phase distribution, as introduced 
in “Methods”. Indicated cells were stained with PI for 
30 min followed by FACScan flow cytometer
Fig.  5 Effect of GSK2334470 (GSK) on PDK1-mTOR-
S6K axis in MK-2206-resistant sublines. a–d After 1  h 
serum starvation, indicated cells were incubated in 
RPMI1640  +  10  % FBS with/without MK-2206 (5  µM) 
or GSK (5 µM). Phosphorylation of PDK1, AKT, mTOR, 
and S6K were detected by western blot at 1.5 and 12 h, 
so were AKT and Actin. GSK3β, p-GSK3β and N-MYC 
were also detected
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